Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) EBITDA (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of EBITDA data on record, last reported at -$24.9 million in Q4 2021.

  • For Q4 2021, EBITDA fell 119.72% year-over-year to -$24.9 million; the TTM value through Dec 2021 reached -$72.3 million, up 3.39%, while the annual FY2025 figure was -$329.0 million, 28.7% down from the prior year.
  • EBITDA reached -$24.9 million in Q4 2021 per COGT's latest filing, down from -$19.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $2.3 million in Q4 2019 and bottomed at -$50.0 million in Q3 2020.
  • Average EBITDA over 4 years is -$13.3 million, with a median of -$10.9 million recorded in 2019.
  • Peak YoY movement for EBITDA: soared 126.73% in 2019, then plummeted 593.6% in 2020.
  • A 4-year view of EBITDA shows it stood at -$8.6 million in 2018, then soared by 126.73% to $2.3 million in 2019, then tumbled by 593.6% to -$11.3 million in 2020, then crashed by 119.72% to -$24.9 million in 2021.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$24.9 million in Q4 2021, -$19.1 million in Q3 2021, and -$16.6 million in Q2 2021.